{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:23:14Z","timestamp":1794248594504,"version":"4.9.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014364","name":"National Children's Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Taighde \u00c9ireann - Research Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.isci.2026.116875","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:12:05Z","timestamp":1784560325000},"page":"116875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A structure-based modeling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia"],"prefix":"10.1016","volume":"29","author":[{"given":"Luke","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksii","family":"Rukhlenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciardha","family":"Carmody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Wynne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris N.","family":"Kholodenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7636-1599","authenticated-orcid":false,"given":"Jonathan","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116875_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/hematology.2020000163","article-title":"Evidence-Based Minireview: Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a focused review","volume":"2020","author":"Patnaik","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.isci.2026.116875_bib2","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1158\/1541-7786.MCR-22-0109","article-title":"Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line","volume":"20","author":"Kurata","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.isci.2026.116875_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hon.3099","article-title":"Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome","volume":"41","author":"Ren","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.116875_bib4","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.116875_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2024-209592","article-title":"The Mutated of KRASgene Determine the Fate of KMT2A-Rearranged AML Patients","volume":"144","author":"Wu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116875_bib6","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2024-202833","article-title":"Contrasting Clinical Implications of NRAS Vs. KRAS Mutations in AML - Only KRAS Mutations Are Associated with Adverse Outcome","volume":"144","author":"Colgan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116875_bib7","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/blood-2023-179966","article-title":"RTK-RAS Signaling Pathway Was Enriched in Rare Acute Myeloid Leukemia Patients with t(16;21)(p11;q22)\/FUS::ERG","volume":"142","author":"Lai","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116875_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.20517\/cdr.2022.130","article-title":"How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?","volume":"6","author":"Perrone","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.isci.2026.116875_bib9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.116875_bib10","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.116875_bib11","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","article-title":"Preclinical efficacy of MEK inhibition in Nras-mutant AML","volume":"124","author":"Burgess","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116875_bib12","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41375-022-01541-0","article-title":"RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia","volume":"36","author":"Decroocq","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.116875_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116875_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116875_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116875_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cels.2018.06.002","article-title":"Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling","volume":"7","author":"Rukhlenko","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.isci.2026.116875_bib17","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1124\/mol.114.095489","article-title":"25 years of small molecular weight kinase inhibitors: potentials and limitations","volume":"87","author":"Fabbro","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.isci.2026.116875_bib18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccell.2016.06.024","article-title":"An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling","volume":"30","author":"Karoulia","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.116875_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.isci.2026.116875_bib20","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2013.07.046","article-title":"Allosteric activation of functionally asymmetric RAF kinase dimers","volume":"154","author":"Hu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116875_bib21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1042\/BST20140025","article-title":"Molecular mechanisms of asymmetric RAF dimer activation","volume":"42","author":"Jambrina","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.isci.2026.116875_bib22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/anie.201509272","article-title":"Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation","volume":"55","author":"Jambrina","year":"2016","journal-title":"Angew. Chem."},{"key":"10.1016\/j.isci.2026.116875_bib23","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.celrep.2015.08.014","article-title":"Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects","volume":"12","author":"Kholodenko","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.116875_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/biom13081212","article-title":"A Combination of Conformation-Specific RAF Inhibitors Overcome Drug Resistance Brought about by RAF Overexpression","volume":"13","author":"Imoto","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.isci.2026.116875_bib25","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a Cancer Dependency Map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116875_bib26","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1021\/acs.molpharmaceut.9b00520","article-title":"Toward Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-Based Convolutional Encoders","volume":"16","author":"Manica","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.isci.2026.116875_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2024.102827","article-title":"New methods for drug synergy prediction: A mini-review","volume":"86","author":"Abbasi","year":"2024","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.isci.2026.116875_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114710","article-title":"Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells","volume":"43","author":"Sevrin","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.116875_bib29","doi-asserted-by":"crossref","first-page":"11100","DOI":"10.1158\/0008-5472.CAN-06-2554","article-title":"Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885","volume":"66","author":"King","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116875_bib30","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/1535-7163.MCT-15-0262","article-title":"BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers","volume":"14","author":"Tang","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2026.116875_bib31","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1158\/1078-0432.CCR-15-1762","article-title":"Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies","volume":"22","author":"Krepler","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116875_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clml.2018.12.009","article-title":"Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia","volume":"19","author":"Maiti","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.isci.2026.116875_bib33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1078-0432.CCR-13-1311","article-title":"Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial","volume":"20","author":"Jain","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116875_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clml.2019.03.015","article-title":"Oral MEK 1\/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study","volume":"19","author":"Ragon","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.isci.2026.116875_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000525566","article-title":"A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations","volume":"145","author":"Desikan","year":"2022","journal-title":"Acta Haematol."},{"key":"10.1016\/j.isci.2026.116875_bib36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.clml.2024.01.007","article-title":"Venetoclax and Cobimetinib in Relapsed\/Refractory AML: A Phase 1b Trial","volume":"24","author":"Konopleva","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.isci.2026.116875_bib37","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2024-208386","article-title":"Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations","volume":"144","author":"Popescu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116875_bib38","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2023-186900","article-title":"Efficacy of Belvarafenib with and without Cobimetinib in Preclinical Models of Ras Pathway-Mutant AML","volume":"142","author":"Levinson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116875_bib39","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.3390\/cancers12123511","article-title":"Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation","volume":"12","author":"Khoury","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.116875_bib40","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2024-204151","article-title":"Belvarafenib Inhibits the Growth of RAS-Mutant Acute Myeloid Leukemia Cell Lines in Vitro and Drives Adaptive Resistance In Vivo","volume":"144","author":"Levinson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116875_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109157","article-title":"A systematic analysis of signaling reactivation and drug resistance","volume":"35","author":"Kholodenko","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.116875_bib42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cncr.33242","article-title":"Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers","volume":"127","author":"Janku","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.isci.2026.116875_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.36401\/JIPO-25-20","article-title":"Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer","volume":"9","author":"Khawaja","year":"2026","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.isci.2026.116875_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166583","article-title":"Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways","volume":"11","author":"Tse","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.116875_bib45","doi-asserted-by":"crossref","first-page":"RP95481","DOI":"10.7554\/eLife.95481.2","article-title":"Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors","volume":"13","author":"Rasmussen","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.isci.2026.116875_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ccr.2008.05.015","article-title":"Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties","volume":"14","author":"le Viseur","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.116875_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.stemcr.2014.12.005","article-title":"Nonirradiated NOD,B6.SCID Il2r\u03b3-\/- Kit(W41\/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells","volume":"4","author":"McIntosh","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.isci.2026.116875_bib48","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/leu.2010.158","article-title":"AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3","volume":"24","author":"Wunderlich","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.116875_bib49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.isci.2026.116875_bib50","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1073\/pnas.1307237110","article-title":"Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids","volume":"110","author":"Kamphorst","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.isci.2026.116875_bib51","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1074\/mcp.TIR118.000853","article-title":"A Novel LC System Embeds Analytes in Pre-formed Gradients for Rapid, Ultra-robust Proteomics","volume":"17","author":"Bache","year":"2018","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.isci.2026.116875_bib52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12964-022-00823-5","article-title":"Reconstruction and analysis of a large-scale binary Ras-effector signaling network","volume":"20","author":"Catozzi","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.isci.2026.116875_bib53","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/nprot.2016.136","article-title":"The MaxQuant computational platform for mass spectrometry-based shotgun proteomics","volume":"11","author":"Tyanova","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.isci.2026.116875_bib54","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","article-title":"The PRIDE database at 20 years: 2025 update","volume":"53","author":"Perez-Riverol","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.isci.2026.116875_bib55","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1093\/bioinformatics\/btx415","article-title":"The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics","volume":"33","author":"Wiredja","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.isci.2026.116875_bib56","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/msb.2013.1","article-title":"Programming biological models in Python using PySB","volume":"9","author":"Lopez","year":"2013","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.isci.2026.116875_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/dmd.120.000161","article-title":"Extension of the Mechanistic Tissue Distribution Model of Rodgers and Rowland by Systematic Incorporation of Lysosomal Trapping: Impact on Unbound Partition Coefficient and Volume of Distribution Predictions in the Rat","volume":"49","author":"Schmitt","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.isci.2026.116875_bib58","first-page":"4020","article-title":"Differences in the pharmacokinetics of daunomycin in normal and leukemic rats","volume":"45","author":"Nooter","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116875_bib59","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment\u2013mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.116875_bib60","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/sj.bjc.6601363","article-title":"P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo","volume":"89","author":"van Tellingen","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.116875_bib61","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1208\/s12248-015-9836-3","article-title":"A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans","volume":"18","author":"Bi","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.isci.2026.116875_bib62","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.106.013359","article-title":"Misuse of the well-stirred model of hepatic drug clearance","volume":"35","author":"Yang","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.isci.2026.116875_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pharmtox-090324-021727","article-title":"Introduction to the Theme \u201cNovel Therapeutics with the Potential to Advance Health Care\u201d","volume":"65","author":"Insel","year":"2025","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.isci.2026.116875_bib64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40262-024-01444-6","article-title":"All You Need to Know About Allometric Scaling: An Integrative Review on the Theoretical Basis, Empirical Evidence, and Application in Human Pharmacology","volume":"64","author":"van Valkengoed","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.isci.2026.116875_bib65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226022534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226022534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:58:54Z","timestamp":1794247134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226022534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589004226022534"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116875","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A structure-based modeling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116875"}}